Variations in Trim5α and Cyclophilin A genes among HIV-1 elite controllers and non controllers in Uganda: a laboratory-based cross-sectional study.


Journal

Retrovirology
ISSN: 1742-4690
Titre abrégé: Retrovirology
Pays: England
ID NLM: 101216893

Informations de publication

Date de publication:
06 07 2020
Historique:
received: 05 05 2020
accepted: 27 06 2020
entrez: 8 7 2020
pubmed: 8 7 2020
medline: 25 6 2021
Statut: epublish

Résumé

Tripartite Motif Containing 5 alpha (TRIM5α), a restriction factor produced ubiquitously in cells and tissues of the body plays an important role in the immune response against HIV. TRIM5α targets the HIV capsid for proteosomal destruction. Cyclophilin A, an intracellular protein has also been reported to influence HIV infectivity in a cell-specific manner. Accordingly, variations in TRIM5α and Cyclophilin A genes have been documented to influence HIV-1 disease progression. However, these variations have not been documented among Elite controllers in Uganda and whether they play a role in viral suppression remains largely undocumented. Our study focused on identifying the variations in TRIM5α and Cyclophilin A genes among HIV-1 Elite controllers and non-controllers in Uganda. From the sequence analysis, the rs10838525 G > A mutation in exon 2 of TRIM5α was only found among elite controllers (30%) while the rs3824949 in the 5'UTR was seen among 25% of the non-controllers. In the Cyclophilin A promoter, rs6850 was seen among 62.5% of the non-controllers and only among 10% elite controllers. Furthermore, rs17860048 in the Cyclophillin A promoter was predominantly seen among elite controllers (30%) and 12.5% non-controllers. From gene expression analysis, we noted that the respective genes were generally elevated among elite controllers, however, this difference was not statistically significant (TRIM5α p = 0.6095; Cyclophilin A p = 0.6389). Variations in TRIM5α and Cyclophillin A promoter may influence HIV viral suppression. The rs10838525 SNP in TRIM5α may contribute to viral suppression among HIV-1 elite controllers. The rs6850 in the cyclophillin A gene may be responsible for HIV-1 rapid progression among HIV-1 non-controllers. These SNPs should be investigated mechanistically to determine their precise role in HIV-1 viral suppression.

Sections du résumé

BACKGROUND
Tripartite Motif Containing 5 alpha (TRIM5α), a restriction factor produced ubiquitously in cells and tissues of the body plays an important role in the immune response against HIV. TRIM5α targets the HIV capsid for proteosomal destruction. Cyclophilin A, an intracellular protein has also been reported to influence HIV infectivity in a cell-specific manner. Accordingly, variations in TRIM5α and Cyclophilin A genes have been documented to influence HIV-1 disease progression. However, these variations have not been documented among Elite controllers in Uganda and whether they play a role in viral suppression remains largely undocumented. Our study focused on identifying the variations in TRIM5α and Cyclophilin A genes among HIV-1 Elite controllers and non-controllers in Uganda.
RESULTS
From the sequence analysis, the rs10838525 G > A mutation in exon 2 of TRIM5α was only found among elite controllers (30%) while the rs3824949 in the 5'UTR was seen among 25% of the non-controllers. In the Cyclophilin A promoter, rs6850 was seen among 62.5% of the non-controllers and only among 10% elite controllers. Furthermore, rs17860048 in the Cyclophillin A promoter was predominantly seen among elite controllers (30%) and 12.5% non-controllers. From gene expression analysis, we noted that the respective genes were generally elevated among elite controllers, however, this difference was not statistically significant (TRIM5α p = 0.6095; Cyclophilin A p = 0.6389).
CONCLUSION
Variations in TRIM5α and Cyclophillin A promoter may influence HIV viral suppression. The rs10838525 SNP in TRIM5α may contribute to viral suppression among HIV-1 elite controllers. The rs6850 in the cyclophillin A gene may be responsible for HIV-1 rapid progression among HIV-1 non-controllers. These SNPs should be investigated mechanistically to determine their precise role in HIV-1 viral suppression.

Identifiants

pubmed: 32631377
doi: 10.1186/s12977-020-00527-z
pii: 10.1186/s12977-020-00527-z
pmc: PMC7339491
doi:

Substances chimiques

Antiviral Restriction Factors 0
Tripartite Motif Proteins 0
TRIM5 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
PPIA protein, human EC 5.2.1.8
Peptidylprolyl Isomerase EC 5.2.1.8

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19

Subventions

Organisme : FIC NIH HHS
ID : D43 TW010132
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010319
Pays : United States
Organisme : NIH HHS
ID : D43TW010319
Pays : United States

Références

Biol Cell. 2009 May;101(5):251-62
pubmed: 19275763
Virology. 2006 Oct 10;354(1):15-27
pubmed: 16887163
Curr Biol. 2006 Jan 10;16(1):95-100
pubmed: 16401428
PLoS One. 2017 Aug 2;12(8):e0182298
pubmed: 28767697
Curr Opin Virol. 2012 Apr;2(2):142-50
pubmed: 22482711
J Virol. 2011 Mar;85(6):3015-9
pubmed: 21177805
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):465-73
pubmed: 27088296
Cold Spring Harb Perspect Med. 2012 May;2(5):a006940
pubmed: 22553496
Int J Clin Exp Med. 2015 Sep 15;8(9):16199-206
pubmed: 26629134
Mol Cell Biochem. 2016 Jan;412(1-2):259-68
pubmed: 26702934
Curr Opin Virol. 2015 Oct;14:47-9
pubmed: 26281011
Retrovirology. 2011 Nov 12;8:93
pubmed: 22078707
J Transl Med. 2016 Sep 02;14:257
pubmed: 27590274
J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):394-398
pubmed: 30063647
AIDS. 2010 Jul 31;24(12):1813-21
pubmed: 20588169
J Gene Med. 2018 Feb;20(2-3):e3004
pubmed: 29282802
PLoS One. 2008;3(12):e3975
pubmed: 19092998
Immunol Res. 2016 Dec;64(5-6):1237-1242
pubmed: 27388872
EMBO Mol Med. 2011 Sep;3(9):513-27
pubmed: 21826793
EMBO J. 2001 Mar 15;20(6):1300-9
pubmed: 11250896
PLoS Pathog. 2008 Feb 8;4(2):e18
pubmed: 18248091
J Virol. 2005 Oct;79(20):12674-80
pubmed: 16188970
Drugs Context. 2018 Feb 21;7:212522
pubmed: 29497452
PLoS Pathog. 2007 Jun;3(6):e88
pubmed: 17590083
J Thromb Haemost. 2020 Jan;18(1):234-242
pubmed: 31519036
Curr Opin Struct Biol. 2015 Apr;31:106-14
pubmed: 25939065
Retrovirology. 2009 Mar 02;6:21
pubmed: 19254360
Gene. 2018 Nov 15;676:95-100
pubmed: 30017737

Auteurs

Sharon Bright Amanya (SB)

Faculty of Health Sciences, Lira University, Lira, Uganda.
Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.

Brian Nyiro (B)

Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.

Francis Waswa (F)

Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.

Bonniface Obura (B)

Faculty of Health Sciences, Lira University, Lira, Uganda.

Rebecca Nakaziba (R)

Faculty of Health Sciences, Lira University, Lira, Uganda.

Eva Nabulime (E)

Center for AIDS Research (CFAR) Lab, Joint Clinical Research Center, Kampala, Uganda.

Ashaba Fred Katabazi (AF)

Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.

Rose Nabatanzi (R)

Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.

Alice Bayiyana (A)

Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.

Gerald Mboowa (G)

Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.
The African Center of Excellence in Bioinformatics and Data Intensive Sciences, the Infectious Diseases Institute, McKinnell Knowledge Centre, Makerere University, Kampala, Uganda.

Alex Kayongo (A)

Makerere University Lung Institute, Kampala, Uganda.

Misaki Wayengera (M)

Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.

Obondo J Sande (OJ)

Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda. ojsande@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH